POINT Biopharma, a wholly owned subsidiary of Eli Lilly and Company
Accelerating Precision Medicine™
Biotechnology · Indiana
About
POINT Biopharma develops next-generation radioligand therapies for the treatment of cancer
Details
- Website: http://www.pointbiopharma.com
- Founded: 2019
- Company Size: 64 employees
- Headquarters: Indianapolis, Indiana
- Specialties: Radioligand, Radiopharmaceutical, Cancer, Oncology